Kemi Williams

Kemi Williams is an accomplished professional with extensive experience in clinical and regulatory affairs, currently serving as Vice President of Clinical & Regulatory Affairs at 54gene since January 2020. In this role, Kemi directs global strategies for clinical trials and regulatory submissions, and has successfully launched a profitable CRO business segment. Previous positions include Director of Clinical Affairs at Siemens Healthineers and Director of Clinical Operations at Roche, where Kemi led key clinical studies and established strategic initiatives. Kemi's advisory roles include membership on boards for HealthPass and QualityMD. Education includes a Bachelor of Science in Computer Science from Loyola Marymount University and an MBA from California State University, Monterey Bay.